About FDA
Percent of death Medical Device Reports (MDRs) reviewed within 5 business days during the month
Dictionary: OSB strives to review medical device adverse events resulting in death within 5 business days of receiving the submission. Timely review of death MDRs can minimize widespread failure of the device, thereby limiting the loss of life due to similar events as the one submitted.
Information is current as of December 31, 2012
Fiscal Year - 2012
| Time | Target | Percent |
|---|---|---|
| Oct 2011 | 90 | 99 |
| Nov 2011 | 90 | 98 |
| Dec 2011 | 90 | 92 |
| Jan 2012 | 90 | 95 |
| Feb 2012 | 90 | 96 |
| Mar 2012 | 90 | 90 |
| Apr 2012 | 90 | 93 |
| May 2012 | 90 | 92 |
| Jun 2012 | 90 | 99 |
| Jul 2012 | 90 | 96 |
| Aug 2012 | 90 | 97 |
| Sep 2012 | 90 | 100 |
FY 2012 Overall: 97%
Number of death MDRs reviewed within 5 business days during the month
Fiscal Year - 2012
| Time | Target | Number |
|---|---|---|
| Oct 2011 | N/A | 585 |
| Nov 2011 | N/A | 506 |
| Dec 2011 | N/A | 545 |
| Jan 2012 | N/A | 578 |
| Feb 2012 | N/A | 592 |
| Mar 2012 | N/A | 617 |
| Apr 2012 | N/A | 484 |
| May 2012 | N/A | 448 |
| Jun 2012 | N/A | 580 |
| Jul 2012 | N/A | 565 |
| Aug 2012 | N/A | 526 |
| Sep 2012 | N/A | 2,731 |
FY 2012 Total: 8,757
Total number of death MDRs reviewed during the month
Fiscal Year - 2012
| Time | Target | Number |
|---|---|---|
| Oct 2011 | N/A | 588 |
| Nov 2011 | N/A | 514 |
| Dec 2011 | N/A | 590 |
| Jan 2012 | N/A | 608 |
| Feb 2012 | N/A | 615 |
| Mar 2012 | N/A | 683 |
| Apr 2012 | N/A | 519 |
| May 2012 | N/A | 488 |
| Jun 2012 | N/A | 587 |
| Jul 2012 | N/A | 586 |
| Aug 2012 | N/A | 543 |
| Sep 2012 | N/A | 2,734 |
FY 2012 Total: 9,055
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.
